The issuance of this patent reinforces the significance of this treatment option for ear, nose and throat (ENT) physicians and their patients, the company said.
It is reported that FinESS sinus treatment is a less-invasive treatment option to break the cycle of chronic rhinosinusitis. FinESS is for patients whose symptoms persist or return, despite antibiotics and steroids, or for patients who do not need, want or cannot have extensive sinus surgery. FinESS can be performed using local anesthetic, with or without mild sedation, the company added.
Peter Keith, chief technology officer and co-founder of Entellus Medical, said: “This notable development is a result of Entellus Medical’s R&D strategy to ensure we stay at the forefront of innovation in providing unique treatment options for patients who suffer from chronic rhinosinusitis.”